U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Advisory Committee on Immunization Practices (ACIP)

CDC Stacks Public Health Publications

The ACIP is a group of medical and public health experts that develops recommendations on the use of vaccines in the civilian population of the United States. The ACIP holds three meetings each year at the Centers for Disease Control and Prevention (CDC), in Atlanta, Georgia to make vaccine recommendations. Meetings are open to the public and available online via webcast. More information on ACIP is available at: https://www.cdc.gov/vaccines/acip/index.html.

(93)
(134)
(235)
(276)
(178)
(127)
(138)
(113)
(96)
(84)
(115)
(117)
(125)
(16)
(24)
(16)
(19)
(13)
(17)
(9)
(8)
(15)
(11)
(6)
(10)
(10)
(5)
(10)
(11)
(5)
(8)
(9)
(6)
(9)
(8)
(7)
(6)
(10)
(5)
(6)
(5)
(6)
(6)
(5)
(5)
(6)
(9)
(3)
(8)
(4)
(3)
(2)
(5)
(3)
(2)
(4)
(3)
(3)
(2)
(2)
(1)
0 of 61
(12)
(32)
(108)
(38)
(11)
(1)
(1)
(49)
(1)
(51)
(49)
(17)
(9)
(1293)
(497)
(7)
0 of 16
(1)
(1)
(1)
(4)
(2)
(1)
(1)
(2)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(5)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(449)
(1)
(1)
(1)
(1)
(1)
(1)
0 of 46
(1)
(1)
(1)
0 of 3
(10)
(5)
(1)
(4)
(2)
(1)
(1)
(3)
(1)
(5)
(1)
(2)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(138)
(1)
(158)
(1)
(33)
(66)
(1)
(1)
(73)
(19)
(2)
(12)
(19)
(1)
(4)
(1)
(1)
(1)
(1)
(2)
(1)
(31)
(2)
(3)
(1)
(2)
(2)
(3)
(6)
(1)
(1)
(10)
(1)
(3)
(2)
(2)
(14)
(2)
(2)
(3)
(5)
(2)
(1)
(9)
(3)
(1)
(2)
(2)
(4)
(1)
(1)
(1)
(1)
(5)
(3)
(1)
(7)
(1)
(10)
(1)
(1)
(10)
(1)
(2)
(2)
(1)
(1)
(2)
(1)
(1)
(7)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(3)
(1)
(12)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(12)
(2)
(2)
(1)
(3)
(9)
(1)
(6)
(1)
(1)
(6)
(2)
(2)
(10)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(3)
(3)
(1)
(11)
(2)
(2)
(4)
(1)
(3)
(13)
(8)
(158)
(111)
(1)
(2)
(2)
(1)
(1)
(11)
(1)
(1)
(10)
(2)
(7)
(2)
(1)
(1)
(1)
(7)
(15)
(4)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(20)
(5)
(199)
(44)
(4)
(3)
(1)
(19)
(2)
(3)
(2)
(82)
(1)
(257)
(6)
(21)
(2)
(1)
(3)
(1)
(1)
(8)
(1)
(4)
(2)
(1)
(1)
(118)
(7)
(5)
(3)
(1)
(1)
(1)
(3)
(1)
(1)
(4)
(35)
(2)
(1)
(16)
(2)
(12)
(1)
(32)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(3)
(22)
(1)
(2)
(2)
(10)
(2)
(2)
(2)
(3)
(1)
(1)
(2)
(23)
(10)
(3)
(1)
(5)
(1)
(1)
(1)
(15)
(1)
(3)
(1)
(9)
(1)
(2)
(4)
(2)
(2)
(1)
(1)
(1)
(2)
(2)
(1)
(4)
(1)
(1)
(1)
(17)
(1)
(1)
(2)
(2)
(1)
(1)
(2)
(3)
(1)
(1)
(3)
(2)
(1)
(2)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(4)
(3)
(9)
(2)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(54)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(21)
(3)
(1)
(5)
(1)
(1)
(15)
(1)
(56)
(1)
(2)
(5)
(1)
(2)
(2)
(1)
(1)
(3)
(5)
(2)
(1)
(15)
(1)
(1)
(2)
(2)
(1)
(3)
(1)
(33)
(2)
(1)
(3)
(2)
(3)
(1)
(19)
(2)
(2)
(4)
(4)
(2)
(1)
(2)
(1)
(2)
(5)
(7)
(1)
(1)
(1)
(7)
(9)
(9)
(1)
(1)
(3)
(1)
(26)
(3)
(1)
(2)
(1)
(1)
(10)
(1)
(2)
(1)
(1)
(39)
(2)
(1)
(1)
(1)
(3)
(4)
(1)
(2)
(3)
(1)
(35)
(1)
(1)
(1)
(7)
(1)
(8)
(1)
(2)
(10)
(11)
(1)
(1)
(1)
(1)
(6)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(167)
(1)
(1)
(5)
(1)
(1)
(4)
(343)
(6)
(3)
(76)
(2)
(2)
(1)
(1)
(1)
(2)
(50)
(6)
(4)
(321)
(1)
(1)
(1)
(192)
(1)
(2)
(17)
(3)
(2)
(3)
(3)
(1)
(1)
(1)
(1)
(6)
(1)
(6)
(110)
(1)
(71)
(1)
(6)
(2)
(3)
(2)
(1)
(1)
(39)
(1)
(10)
(1)
(11)
(4)
(26)
(15)
(2)
(1)
(2)
(1)
(3)
(10)
(4)
(15)
(2)
(13)
(2)
(18)
(6)
(2)
(1)
(1)
(2)
(2)
(4)
(173)
(18)
(2)
(1)
(11)
(5)
(2)
(2)
(2)
(1)
(1)
(1)
(2)
(2)
(2)
(2)
(2)
(2)
(2)
(3)
(1)
(1)
(1)
(1)
(12)
(3)
(2)
(4)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(10)
(1)
(4)
(1)
(1)
(31)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(3)
(2)
(6)
(1)
(13)
(4)
(2)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(42)
(1)
(2)
(8)
(1)
(1)
(11)
(1)
(1)
(6)
(28)
(1)
(1)
(1)
(2)
(1)
(7)
(1)
(9)
(1)
(2)
(1)
(2)
(1)
(2)
(3)
(4)
(1)
(1)
(3)
(14)
(3)
(1)
(10)
(2)
(1)
(104)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(71)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(15)
(1)
(3)
(2)
(3)
(3)
(4)
(15)
(12)
(3)
(2)
(4)
(3)
(1)
(6)
(1)
(7)
(1)
(1)
(5)
(1)
(13)
(2)
(1)
(1)
(1)
(1)
(2)
(1)
(5)
(2)
(1)
(1)
(1)
(1)
(1)
(3)
(4)
(1)
(1)
(1)
(4)
(1)
(7)
(1)
(3)
(6)
(2)
(1)
(2)
(1)
(2)
(1)
(7)
(1)
(1)
(1)
(2)
(1)
(1)
(29)
(1)
(152)
(1)
(5)
(1)
(1)
(1)
(3)
(2)
(56)
(1)
(1)
(34)
(1)
(8)
(1)
(1)
(1)
(1)
(1)
(56)
(1)
(2)
(1)
(6)
(1)
(1)
(1)
(35)
(2)
(1)
(2)
(1)
(1)
(6)
(1)
(1)
(1)
(1)
(1)
(17)
(1)
(1)
(8)
(1)
(91)
(3)
(1)
(2)
(4)
(1)
(1)
(11)
(2)
(3)
(1)
(3)
(1)
(4)
(2)
(6)
(2)
(2)
(1)
(8)
(2)
(1)
(5)
(1)
(10)
(13)
(1)
(6)
(1)
(2)
(1)
(6)
(1)
(35)
(1)
(9)
(1)
(64)
(1)
(6)
(3)
(2)
(1)
(2)
(1)
(2)
(2)
(1)
(26)
(1)
(1)
(3)
(1)
(1)
(4)
(1)
(1)
(3)
(3)
(1)
(16)
(1)
(1)
(1)
(4)
(2)
(14)
(1)
(1)
(4)
(3)
(2)
(11)
(1)
(1)
(1)
(4)
(5)
(2)
(4)
(11)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(2)
(1)
(1)
(1)
(10)
(5)
(2)
(1)
(53)
(13)
(4)
(48)
(10)
(13)
(1)
(1)
(1)
(2)
(1)
(4)
(18)
(12)
(1)
(1)
(3)
(9)
(1)
(2)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(2)
(32)
(5)
(2)
(13)
(5)
(1)
(1)
(2)
(19)
(1)
(6)
(2)
(1)
(2)
(1)
(2)
(2)
(1)
(1)
(11)
(2)
(1)
(4)
(2)
(1)
(1)
(2)
(1)
(1)
(26)
(2)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(11)
(1)
(1)
(1)
(2)
(1)
(2)
(1)
(1)
(2)
(3)
(2)
(8)
(1)
(5)
(4)
(8)
(5)
(1)
(1)
(1)
(1)
(1)
(21)
(1)
(1)
(2)
(1)
(7)
(3)
(2)
(4)
(2)
(1)
(2)
(2)
(1)
(1)
(630)
(17)
(2)
(1)
(1)
(5)
(1)
(1)
(24)
(22)
(4)
(4)
(1)
(1)
(13)
(379)
(1)
(28)
(23)
(23)
(1)
(1)
(1)
(21)
(1)
(1)
(9)
(2)
(51)
(2)
(1)
(11)
(18)
(2)
(2)
(5)
(3)
(12)
(2)
(170)
(2)
(23)
(2)
(10)
(4)
(2)
(2)
(2)
(11)
(2)
(2)
(2)
(2)
(43)
(2)
(4)
0 of 1000
(1)
(1)
(3)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(3)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(3)
(2)
(1)
(1)
(1)
(7)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(7)
(1)
(9)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(39)
(2)
(1)
(8)
(16)
(1)
(4)
(4)
(2)
(3)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(4)
(2)
(1)
(1)
(3)
(23)
(1)
(1)
(8)
(2)
(1)
(11)
(1)
(1)
(1)
(15)
(1)
(1)
(14)
(1)
(1)
(5)
(1)
(2)
(1)
(1)
(3)
(8)
(21)
(1)
(1)
(9)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(16)
(2)
(1)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(9)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(10)
(1)
(1)
(2)
(7)
(1)
(1)
(5)
(1)
(8)
(2)
(5)
(10)
(2)
(1)
(1)
(2)
(2)
(2)
(22)
(3)
(4)
(4)
(4)
(3)
(1)
(22)
(1)
(7)
(1)
(4)
(2)
(2)
(1)
(4)
(4)
(2)
(32)
(2)
(1)
(1)
(1)
(6)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(3)
(1)
(31)
(3)
(1)
(5)
(1)
(1)
(2)
(1)
(1)
(3)
(1)
(2)
(1)
(7)
(1)
(4)
(1)
(1)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(4)
(2)
(2)
(3)
(1)
(7)
(1)
(2)
(1)
(1)
(10)
(10)
(1)
(11)
(2)
(6)
(1)
(1)
(2)
(2)
(1)
(1)
(2)
(1)
(1)
(9)
(4)
(2)
(1)
(1)
(1)
(5)
(8)
(1)
(1)
(5)
(7)
(1)
(1)
(1)
(1)
(3)
(2)
(2)
(1)
(12)
(1)
(2)
(5)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(5)
(1)
(1)
(2)
(1)
(51)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(2)
(1)
(1)
(4)
(2)
(1)
(15)
(1)
(4)
(8)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(4)
(7)
(1)
(3)
(3)
(1)
(4)
(4)
(1)
(1)
(3)
(5)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(14)
(20)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(2)
(12)
(1)
(1)
(1)
(1)
(9)
(1)
(8)
(1)
(1)
(1)
(1)
(1)
(2)
(8)
(1)
(1)
(1)
(2)
(3)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(7)
(1)
(11)
(1)
(2)
(2)
(1)
(1)
(1)
(13)
(1)
(1)
(1)
(1)
(6)
(1)
(1)
(7)
(2)
(1)
(1)
(1)
(4)
(3)
(1)
(1)
(1)
(1)
(11)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(7)
(21)
(2)
(1)
(3)
(7)
(3)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(15)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(34)
(2)
(1)
(2)
(8)
(3)
(1)
(1)
(1)
(1)
(2)
(1)
(15)
(1)
(1)
(1)
(5)
(1)
(13)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(7)
(1)
(9)
(1)
(1)
(1)
(1)
(1)
(1)
(7)
(1)
(14)
(9)
(1)
(1)
(1)
(1)
(2)
(1)
(4)
(1)
(1)
(1)
(1)
(1)
(3)
(11)
(1)
(37)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(8)
(1)
(1)
(1)
(4)
(2)
(10)
(1)
(8)
(1)
(1)
(1)
(1)
(1)
(5)
(1)
(5)
(3)
(2)
(2)
(1)
(1)
(4)
(6)
(8)
(1)
(6)
(1)
(2)
(1)
(3)
(5)
(2)
(4)
(2)
(5)
(1)
(2)
(1)
(1)
(1)
(2)
(1)
(5)
(1)
(11)
(2)
(1)
(3)
(1)
(4)
(2)
(1)
(12)
(2)
(2)
(6)
(1)
(9)
(2)
(1)
(2)
(1)
(7)
(7)
(1)
(1)
(2)
(1)
(11)
(8)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(3)
(54)
(2)
(4)
(4)
(1)
(1)
(2)
(1)
(3)
(1)
(1)
(6)
(9)
(3)
(1)
(1)
(1)
(1)
(2)
(2)
(3)
(1)
(1)
(4)
(1)
(3)
(1)
(1)
(6)
(3)
(2)
(2)
(1)
(1)
(1)
(4)
(7)
(2)
(4)
(1)
(8)
(1)
(1)
(25)
(1)
(1)
(10)
(17)
(1)
(2)
(1)
(1)
(2)
(1)
(1)
(6)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(14)
(4)
(3)
(2)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(18)
(1)
(2)
(1)
(1)
(7)
(1)
(2)
(10)
(1)
(1)
(1)
(1)
(30)
(2)
(2)
(2)
(1)
(1)
(1)
(1)
(2)
(3)
(2)
(1)
(3)
(1)
(2)
(1)
(19)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(8)
(1)
(1)
(30)
(5)
(1)
(11)
(3)
(1)
(1)
(2)
(1)
(2)
(2)
(8)
(1)
(1)
(1)
(1)
(1)
(7)
(4)
(2)
(1)
(4)
(2)
(1)
(2)
(1)
(4)
(1)
(1)
(1)
(1)
(2)
(1)
(8)
(2)
(1)
(1)
(2)
(45)
(1)
(1)
(7)
(1)
(3)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(10)
(1)
(1)
(1)
(10)
(1)
(1)
(13)
(1)
(8)
(7)
(2)
(2)
(1)
(8)
(8)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(7)
(8)
(2)
(1)
(32)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(10)
(1)
(1)
(2)
(1)
(2)
(1)
(3)
(5)
(4)
(1)
(2)
(2)
(1)
(1)
(9)
(1)
(2)
(2)
(10)
(1)
(1)
(1)
(2)
(1)
(5)
(1)
(1)
(4)
(2)
(2)
(26)
(1)
(1)
(24)
(1)
(1)
(1)
(3)
(1)
(1)
(2)
(4)
(5)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(5)
(4)
(2)
(2)
(1)
(1)
(11)
(3)
(1)
(4)
(1)
(1)
(5)
(1)
(2)
(9)
(1)
(1)
(6)
(2)
(1)
(3)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
0 of 897
(2)
(1)
(1)
(3)
(1)
(1)
(2)
(2)
(5)
(24)
(3)
(4)
(6)
(1)
(16)
(21)
(9)
(1)
(1)
(1)
(1)
(6)
(3)
(1)
(4)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(3)
(1)
(8)
(1)
(3)
(6)
(1)
(1)
(2)
(14)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(29)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(2)
(50)
(113)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(9)
(1)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(6)
(1)
(1)
(2)
(2)
(9)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(1)
(1)
(2)
(4)
(1)
(1)
(1)
(5)
(1)
(11)
(1)
(2)
(1)
(1)
(4)
(2)
(1)
(1)
(1)
(1)
(4)
(2)
(1)
(1)
(1)
(6)
(1)
(1)
(8)
(1)
(2)
(7)
(5)
(1)
(1)
(5)
(2)
(6)
(1)
(1)
(1)
(12)
(1)
(9)
(2)
(1)
(5)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(4)
(3)
(4)
(1)
(16)
(11)
(1)
(8)
(6)
(1)
(3)
(1)
(5)
(1)
(3)
(25)
(3)
(8)
(1)
(1)
(1)
(30)
(4)
(6)
(1)
(44)
(30)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(9)
(1)
(10)
(14)
(2)
(10)
(1)
(90)
(1)
(1)
(1)
(1)
(1)
(1)
(7)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(46)
(4)
(3)
(2)
(66)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(83)
(1)
(1)
(1)
(2)
(53)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(3)
(2)
(6)
(9)
(1)
(10)
(1)
(1)
(2)
(3)
(6)
(2)
(1)
(5)
(4)
(1)
(3)
(2)
(1)
(1)
(13)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(10)
(1)
(22)
(3)
(7)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(4)
(1)
(1)
(1)
(4)
(9)
(1)
(2)
(1)
(1)
(1)
(3)
(1)
(2)
(3)
(3)
(1)
(2)
(10)
(1)
(6)
(1)
(1)
(11)
(1)
(1)
(1)
(1)
(3)
(1)
(7)
(1)
(1)
(1)
(1)
(1)
(13)
(1)
(14)
(547)
(1)
(1)
(1)
(6)
(1)
(3)
(1)
(4)
(10)
(1)
(15)
(11)
(14)
(1)
(4)
(4)
(1)
(2)
(2)
(5)
(1)
(4)
(1)
(162)
(1)
(5)
(1)
(3)
(7)
(3)
(1)
(33)
(2)
(14)
(3)
(3)
(9)
(2)
(1)
(10)
(1)
(2)
(30)
(6)
(1)
(4)
(4)
(5)
(2)
(7)
(1)
(6)
(2)
(1)
(19)
(15)
(1)
(1)
(9)
(5)
(1)
(2)
(2)
(18)
(3)
(5)
(46)
(2)
(1)
(2)
(3)
(2)
(1)
(3)
(4)
(1)
(5)
(1)
(1)
(4)
(3)
(1)
(1)
(7)
(2)
(2)
(3)
(1)
(1)
(1)
(2)
(1)
(1)
(2)
(3)
(7)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(10)
(3)
(2)
(3)
(1)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(11)
(1)
(1)
(1)
(3)
(1)
(2)
(1)
0 of 463
(1)
(74)
(1)
(1)
(1624)
(32)
(7)
(8)
(1)
(14)
(102)
(200)
(10)
(11)
(32)
(1292)
(1)
(39)
(2)
(2)
(63)
(1)
(1)
(1)
(1)
0 of 25
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
0 of 17
(1)
0 of 1
Showing 581 - 600 of 2197 results
  • Use of COVID19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen Johnson Johnson and MRNA COVID19 Vaccines PfizerBioNTech and Moderna Update From the Advisory Committee on Immunization Practices United States July 2021
    Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and MRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update From the Advisory Committee on Immunization Practices — United States, July 2021
    Rosenblum, Hannah G. ;
    Hadler, Stephen C.
    August 10, 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    What is already known about this topic? Rare serious adverse events have been reported after COVID-19 vaccination, including Guillain-Barré syndrome (GBS) and thrombosis with thrombocytopenia syndrome (TTS) after Janssen COVID-19 vaccination and myocarditis after mRNA (Pfizer-BioNTech and Moderna) COVID-19 vaccination.What is added by this report? ...
    Supporting Files Public Domain
  • General best practice guidelines for immunization best practices guidance of the Advisory Committee on Immunization Practices ACIP
    General best practice guidelines for immunization : best practices guidance of the Advisory Committee on Immunization Practices (ACIP)
    United States, Advisory Committee on Immunization Practices.  ...
    August 5, 2021
    The Centers for Disease Control and Prevention (CDC) recommends routine vaccination to prevent 17 vaccine-preventable diseases that occur in infants, children, adolescents, or adults. This report provides information for clinicians and other health care providers about concerns that commonly arise when vaccinating persons of various ages. Providers ...
    Superseded Public Domain
  • Benefits and risks of COVID19 vaccines Work Group considerations
    Benefits and risks of COVID-19 vaccines : Work Group considerations
    Mbaeyi, Sarah A
    07/22/2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    06-COVID-Mbaeyi-508.pdf
    Public Domain
  • Data and clinical considerations for additional doses in immunocompromised people
    Data and clinical considerations for additional doses in immunocompromised people
    Oliver, Sara E.
    07/22/2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    07-COVID-Oliver-508.pdf
    Public Domain
  • GuillainBarre Syndrome GBS after Janssen COVID19 vaccine Vaccine Adverse Event Reporting System VAERS
    Guillain-Barré Syndrome (GBS) after Janssen COVID-19 vaccine : Vaccine Adverse Event Reporting System (VAERS)
    Alimchandani, Meghna
    07/22/2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    02-COVID-Alimchandani-508.pdf
    Public Domain
  • COVID19 Vaccine Safety Technical VaST Work Group assessment
    COVID-19 Vaccine Safety Technical (VaST) Work Group assessment
    Lee, Grace M. ;
    Hopkins, Robert H.
    07/22/2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    04-COVID-Lee-508.pdf
    Public Domain
  • ACIP COVID19 Vaccines Work Group
    ACIP COVID-19 Vaccines Work Group
    Daley, Matt F.
    07/22/2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    01-COVID-Daley-508.pdf
    Public Domain
  • COVID19 vaccines in adults benefitrisk discussion
    COVID-19 vaccines in adults : benefit-risk discussion
    Rosenblum, Hannah
    07/22/2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    05-COVID-Rosenblum-508.pdf
    Public Domain
  • Rapid cycle analysis RCA to monitor the safety of COVID19 vaccines in near realtime within the Vaccine Safety Datalink GuillainBarr syndrome GBS
    Rapid cycle analysis (RCA) to monitor the safety of COVID-19 vaccines in near real-time within the Vaccine Safety Datalink : Guillain-Barré syndrome (GBS)
    Klein, Nicola P.
    07/22/2021 | ACIP: Coronavirus Disease 2019 (COVID-19)
    03-COVID-Klein-508.pdf
    Public Domain
  • Meeting of the Advisory Committee on Immunization Practices ACIP July 22 2021 summary minutes
    Meeting of the Advisory Committee on Immunization Practices (ACIP), July 22, 2021, summary minutes
    United States. Advisory Committee on Immunization Practices.
    07/22/2021 | ACIP Meetings Minutes
    Summary Minutes, July 22, 2021
    Public Domain
  • Agenda Meeting of the Advisory Committee on Immunization Practices ACIP July 22 2021 Atlanta Georgia
    [Agenda] : Meeting of the Advisory Committee on Immunization Practices (ACIP) : July 22, 2021, Atlanta, Georgia
    United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group.
    July 21, 2021 | ACIP: Meeting Agenda, Minutes, etc.
    agenda-2021-07-22-508.pdf
    Public Domain
  • Use of mRNA COVID19 Vaccine After Reports of Myocarditis Among Vaccine Recipients Update from the Advisory Committee on Immunization Practices United States June 2021
    Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
    Gargano, Julia W. ;
    Wallace, Megan
    07/09/2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine and the Moderna COVID-19 (mRNA-1273) vaccine,| and the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for their use in persons aged ≥16 years and ≥18 years, respe ...
    Supporting Files
  • MMWR Morbidity and Mortality Weekly Report Early Release Vol 70 July 6 2021
    MMWR: Morbidity and Mortality Weekly Report: Early Release / Vol. 70, July 6, 2021
    Yard, Ellen ;
    Radhakrishnan, Lakshmi
    07/06/2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    What is already known about this topic? An elevated risk for myocarditis among mRNA COVID-19 vaccinees has been observed, particularly in males aged 12–29 years.What is added by this report? On June 23, 2021, the Advisory Committee on Immunization Practices concluded that the benefits of COVID-19 vaccination to individual persons and at the populat ...
    Supporting Files
  • Evidence to recommendation framework Use of 15valent and 20valent Pneumococcal Conjugate Vaccines in Adults
    Evidence to recommendation framework: Use of 15-valent and 20-valent Pneumococcal Conjugate Vaccines in Adults
    Kobayashi, Miwako
    06/25/2021 | ACIP: Pneumococcal
    05-Pneumococcal-Kobayashi-508.pdf
    Public Domain
  • Zoster Vaccines session Burden of Herpes Zoster in immunocompromised adults
    Zoster Vaccines session : Burden of Herpes Zoster in immunocompromised adults
    Anderson, Tara
    06/25/2021 | ACIP: Herpes Zoster
    02-Zoster-Anderson-508.pdf
    Public Domain
  • Pneumococcal vaccines
    Pneumococcal vaccines
    Poehling, Katherine A.
    06/25/2021 | ACIP: Pneumococcal
    01-Pneumococcal-Poehling-508.pdf
    Public Domain
  • Use of Recombinant Zoster vaccine RZV in immunocompromised populations
    Use of Recombinant Zoster vaccine (RZV) in immunocompromised populations
    Widenmaier, Robyn
    06/25/2021 | ACIP: Herpes Zoster
    03-Zoster-Widenmaier-508.pdf
    Public Domain
  • Current epidemiology of pneumococcal disease United States 2019 updates
    Current epidemiology of pneumococcal disease, United States- 2019 updates
    Gierke, Ryan
    06/25/2021 | ACIP: Pneumococcal
    02-Pneumococcal-Gierke-508.pdf
    Public Domain
  • Zoster Vaccines session Introduction
    Zoster Vaccines session : Introduction
    Lee, Grace M.
    06/25/2021 | ACIP: Herpes Zoster
    01-Zoster-Lee-508.pdf
    Public Domain
  • GRADE 15valent and 20valent Pneumococcal Conjugate Vaccine use in adults
    GRADE: 15-valent and 20-valent Pneumococcal Conjugate Vaccine use in adults
    Farrar, Jennifer
    06/25/2021 | ACIP: Pneumococcal
    04-Pneumococcal-Farrar-508.pdf
    Public Domain
581 - 600 / 2197